Information  X 
Enter a valid email address

Gamma Communications (GAMA)

  Print      Mail a friend

Wednesday 25 March, 2020

Gamma Communications

Issue of Equity

RNS Number : 5644H
Gamma Communications PLC
25 March 2020
 

 

25 March 2020

Gamma Communications plc

("Gamma Communications plc" or the "Company")

 

Issue of Equity

 

Gamma Communications plc ("Gamma"), a leading technology-based provider of communications services to the business markets in the UK and the Netherlands, today announces that it has issued 69,024 new ordinary shares of 0.25 pence each in the capital of the Company.

 

Consideration Shares

Further to the announcement on 2 March 2020, 69,024 new ordinary shares in Gamma have been issued as consideration to the shareholders of Exactive Holdings Limited ("Exactive"), a unified communications specialist based in Dunfermline, Scotland. 

 

Application has been made to the London Stock Exchange for the admission of 69,024 new ordinary shares to trading on AIM. Admission is expected to take place at 8.00am on 31 March 2020. The Company's total issued share capital following admission will consist of 94,872,661 ordinary shares of 0.25 pence each with one voting right per share. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

 

Gamma Communications plc

Andrew Taylor, CEO

Andrew Belshaw, Chief Financial Officer

Malcolm Goddard, Company Secretary

 

Tel: +44 ( 0)333 006 5972

 

Investec Bank plc (NOMAD & Broker)

Patrick Robb / Sebastian Lawrence / Virginia Bull

 

 

 

 

Tel: +44 (0)20 7597 5970

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IOEFELFLBXLZBBF

a d v e r t i s e m e n t